Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs

Neuropsychiatric disorders are the third leading cause of global disease burden. Current pharmacological treatment for these disorders is inadequate, with often insufficient efficacy and undesirable side effects. One reason for this is that the links between molecular drug action and neurobehavioral...

Descripción completa

Detalles Bibliográficos
Autores principales: Noori, Hamid R., Mervin, Lewis H., Bokharaie, Vahid, Durmus, Özlem, Egenrieder, Lisamon, Fritze, Stefan, Gruhlke, Britta, Reinhardt, Giulia, Schabel, Hans-Hendrik, Staudenmaier, Sabine, Logothetis, Nikos K., Bender, Andreas, Spanagel, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224407/
https://www.ncbi.nlm.nih.gov/pubmed/30410047
http://dx.doi.org/10.1038/s41467-018-07239-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224407/
https://www.ncbi.nlm.nih.gov/pubmed/30410047
http://dx.doi.org/10.1038/s41467-018-07239-1

Ejemplares similares